2 completed, 1 terminated. 2 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 2 | Completed 2 |
| Phase 2 | 1 | Terminated 1 |
Follow Serum chemistry: new trials by email Literature Review of Serum chemistry trials Research Report on Serum chemistry
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Assessment of KM-001 - Safety, Tolerability, and Efficacy in Patients With PPPK1 or PC KM-001 cream 1% 12 weeks treatment., Physical Examination, Vital Signs - Punctate Palmoplantar Keratoderma Type 1, Pachyonychia Congenita | Phase 1 | Completed | Orvida Pharma (formerly Kamari Pharma) | 18 | 2023-03-06 | 2025-01-15 |
| Study Designed to Evaluate Safety and Efficacy of 1% Topical Formulation of KM-001 on Type 1 Punctate Palmoplantar Keratoderma or Pachyonychia Congenita Diseases Serum chemistry, Hematology, Urinalysis - Punctate Palmoplantar Keratoderma Type 1, Pachyonychia Congenita | Phase 1 | Completed | Orvida Pharma (formerly Kamari Pharma) | 14 | 2022-07-17 | 2025-01-07 |
| Single Agent JNJ-56022473 in MDS and AML Patients FAILING HYPOMETHYLATING AGENT BASED THERAPY JNJ-56022473, Bone marrow analyses and CBC with differential, Flow cytometry analyses - Myelodysplastic Syndrome (MDS), Acute Myeloid Leukemia (AML) | Phase 2 | Terminated | GWT-TUD GmbH | 25 | 2016-07-01 | 2018-10-25 |
Keratosis palmoplantaris papulosa (2) · Pachyonychia Congenita (2) · Leukemia, Myeloid, Acute (1) · Myelodysplastic Syndromes (1)
Orvida Pharma (formerly Kamari Pharma) (2) · GWT-TUD GmbH (1)
France (1) · Germany (1) · Israel (1) · United Kingdom (1)